Comparison
While GHK-Cu acts as a tissue-remodeling and wound-healing signal, enhancing skin regeneration, angiogenesis, and repair while reducing inflammation and oxidative damage in experimental models31383, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While GHK-Cu works as an endogenous tripeptide, Gly-His-Lys, that chelates Cu²⁺ and modulates gene expression, stimulating collagen, elastin, proteoglycan, and glycosaminoglycan synthesis while exerting antioxidant and anti-inflammatory effects31383, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
GHK-Cu is 3 amino acids long, whereas Tirzepatide is longer as it has a length of 39 amino acids. GHK-Cu is made up of a sequence of Glycine, Histidine, Lysine. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
GHK-Cu
Not clearly established in the current dataset.
Tirzepatide
Glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1 receptor (GLP1R) 24
GHK-Cu
Not assigned in the current dataset.
Tirzepatide
Not assigned in the current dataset.